Given LY6G6D has also been implicated in the immune resistance that is characteristic of MSS disease [107], targeting LY6G6D may provide a novel opportunity for the treatment of MSS CRC patients. Here, LY6G6D is linked to Marinesco-Sjogren syndrome.